(Q37765064)

22 August 2017

1 reference

title

Statin therapy--Part II: Clinical considerations for cardiovascular disease (English)

1 reference

22 August 2017

1 reference

cardiovascular disease

1 reference

Benjamin Sadowitz

1

1 reference

22 August 2017

Keri Seymour

series ordinal

2

1 reference

22 August 2017

Michael J Costanza

series ordinal

3

1 reference

22 August 2017

Vivian Gahtan

series ordinal

4

1 reference

22 August 2017

publication date

14 June 2010

1 reference

Vascular and Endovascular Surgery

22 August 2017

published in

1 reference

22 August 2017

volume

44

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

421-433

1 reference

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

The effect of statins in heart failure: beyond its cholesterol-lowering effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Cardiac myocyte necrosis induced by angiotensin II

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Angiotensin receptors and their antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statins in heart failure. Beyond the lipid lowering effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statins in the treatment of chronic heart failure: biological and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Selenoprotein synthesis and side-effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

The endotoxin-lipoprotein hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Discontinuation of statin treatment in stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Nitric oxide: an endogenous modulator of leukocyte adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Recurrent cerebrovascular episodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

The role of platelets in ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statins as potential therapeutic agents in neuroinflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statin therapy-evidence beyond lipid lowering contributing to plaque stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

The benefit of statins in non-cardiac vascular surgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society f

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Growth predictors and prognosis of small abdominal aortic aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Medical management of abdominal aortic aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Simvastatin Attenuates the Activity of Matrix Metalloprotease-9 in Aneurysmal Aortic Tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effects of colestipol-niacin therapy on human femoral atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statin therapy improves cardiovascular outcome of patients with peripheral artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Management of dyslipidemia with statins in the patient with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Potential nontraditional applications of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Medical treatment of peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Risks associated with statin therapy: a systematic overview of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statin-associated adverse effects beyond muscle and liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

Pharmacological interactions of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1538574410363833

21 January 2018

Identifiers

DOI

10.1177/1538574410363833

1 reference

22 August 2017

1 reference